APYX MEDICAL CORPORATION Financials Apyx Medical Corporation
Equities
APYX
US03837C1062
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.45 USD | -2.03% |
|
+9.85% | -44.66% |
| Apr. 05 | Archon Capital Management Engages with Apyx Medical Corporation | CI |
| Apr. 01 | Stavros G. Vizirgianakis Engages in Discussions with Apyx Medical Corporation | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 289.1 | 246.8 | 440.3 | 80.96 | 90.77 | 50.23 | - | - |
| Enterprise Value (EV) 1 | 289.1 | 246.8 | 440.3 | 80.96 | 90.77 | 50.23 | 50.23 | 50.23 |
| P/E ratio | -14.6 x | -20.6 x | -29.1 x | -3.49 x | -4.85 x | -1.86 x | -2.08 x | -2.99 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 10.3 x | 8.91 x | 9.07 x | 1.82 x | 1.73 x | 1.01 x | 0.92 x | 0.79 x |
| EV / Revenue | 10.3 x | 8.91 x | 9.07 x | 1.82 x | 1.73 x | 1.01 x | 0.92 x | 0.79 x |
| EV / EBITDA | -17 x | -17 x | -50 x | -5.27 x | -6.78 x | -2.9 x | -3.45 x | -7.74 x |
| EV / FCF | -14.6 x | -14.8 x | -39.4 x | -3.8 x | -15.7 x | -1.84 x | -1.78 x | -7.34 x |
| FCF Yield | -6.84% | -6.75% | -2.54% | -26.3% | -6.37% | -54.4% | -56.2% | -13.6% |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 34,168 | 34,275 | 34,344 | 34,598 | 34,644 | 34,644 | - | - |
| Reference price 2 | 8.460 | 7.200 | 12.82 | 2.340 | 2.620 | 1.450 | 1.450 | 1.450 |
| Announcement Date | 3/16/20 | 3/31/21 | 3/17/22 | 3/16/23 | 3/21/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 28.15 | 27.71 | 48.52 | 44.51 | 52.35 | 49.94 | 54.52 | 63.77 |
| EBITDA 1 | -16.96 | -14.5 | -8.802 | -15.37 | -13.39 | -17.31 | -14.55 | -6.488 |
| EBIT 1 | -20.91 | -20.08 | -14.45 | -23.56 | -17.26 | -22.82 | -20.58 | -11.34 |
| Operating Margin | -74.28% | -72.47% | -29.78% | -52.94% | -32.97% | -45.69% | -37.75% | -17.78% |
| Earnings before Tax (EBT) 1 | -19.91 | -19.41 | -14.82 | -22.91 | -21.28 | -27.29 | -24.86 | -16.98 |
| Net income 1 | -19.65 | -11.9 | -15.17 | -23.18 | -18.71 | -27.68 | -25.17 | -17.28 |
| Net margin | -69.79% | -42.93% | -31.27% | -52.09% | -35.75% | -55.43% | -46.16% | -27.09% |
| EPS 2 | -0.5800 | -0.3500 | -0.4400 | -0.6700 | -0.5400 | -0.7800 | -0.6960 | -0.4850 |
| Free Cash Flow 1 | -19.78 | -16.65 | -11.17 | -21.29 | -5.782 | -27.31 | -28.22 | -6.843 |
| FCF margin | -70.24% | -60.07% | -23.03% | -47.83% | -11.05% | -54.69% | -51.75% | -10.73% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/16/20 | 3/31/21 | 3/17/22 | 3/16/23 | 3/21/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 11.83 | 16.82 | 12.49 | 10.29 | 9.114 | 12.61 | 12.14 | 13.57 | 11.98 | 14.66 | 9.527 | 12.22 | 12.22 | 15.97 | 10.56 |
| EBITDA 1 | -2.73 | -0.3 | -3.994 | -3.384 | -3.878 | -4.116 | -3.997 | -1.623 | -3.073 | -4.693 | -5.412 | -4.361 | -4.496 | -3.067 | -2.974 |
| EBIT 1 | -3.968 | -1.692 | -5.871 | -5.976 | -5.782 | -5.933 | -5.611 | -1.235 | -4.637 | -5.776 | -6.724 | -5.686 | -5.858 | -4.548 | -4.558 |
| Operating Margin | -33.54% | -10.06% | -46.99% | -58.06% | -63.44% | -47.05% | -46.21% | -9.1% | -38.72% | -39.39% | -70.58% | -46.53% | -47.96% | -28.48% | -43.14% |
| Earnings before Tax (EBT) 1 | -4.161 | -1.876 | -5.898 | -5.354 | -5.745 | -5.914 | -5.799 | -0.953 | -4.993 | -9.537 | -7.836 | -6.824 | -6.996 | -5.686 | -5.408 |
| Net income 1 | -4.222 | -2.003 | -5.945 | -5.426 | -5.764 | -6.049 | -3.483 | -0.994 | -4.629 | -9.607 | -7.941 | -6.901 | -7.082 | -5.78 | -5.466 |
| Net margin | -35.69% | -11.91% | -47.59% | -52.72% | -63.24% | -47.97% | -28.69% | -7.33% | -38.65% | -65.52% | -83.35% | -56.47% | -57.97% | -36.19% | -51.74% |
| EPS 2 | -0.1200 | -0.0600 | -0.1700 | -0.1600 | -0.1700 | -0.1700 | -0.1000 | -0.0300 | -0.1300 | -0.2800 | -0.2160 | -0.1980 | -0.1960 | -0.1720 | -0.1533 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/11/21 | 3/17/22 | 5/12/22 | 8/11/22 | 11/10/22 | 3/16/23 | 5/11/23 | 8/10/23 | 11/9/23 | 3/21/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -19.8 | -16.6 | -11.2 | -21.3 | -5.78 | -27.3 | -28.2 | -6.84 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 1.3 | 0.58 | 0.72 | 1.01 | 0.53 | 1 | 1 | 1.03 |
| Capex / Sales | 4.62% | 2.1% | 1.49% | 2.27% | 1.02% | 2% | 1.83% | 1.61% |
| Announcement Date | 3/16/20 | 3/31/21 | 3/17/22 | 3/16/23 | 3/21/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.45
USD
Average target price
3.625
USD
Spread / Average Target
+150.00%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -44.66% | 50.23M | |
| -2.31% | 187B | |
| -3.20% | 106B | |
| -5.04% | 66.9B | |
| +0.20% | 49.45B | |
| +17.29% | 48B | |
| +4.06% | 40.84B | |
| +2.07% | 26.48B | |
| +2.36% | 26.25B | |
| +12.96% | 24.62B |
- Stock Market
- Equities
- APYX Stock
- Financials Apyx Medical Corporation
